Cabot Undervalued Stocks Advisor Weekly Update
U.S. stocks continue to defy gravity, with their audacious 2019 year-to-date gains mirroring their equally extreme fourth quarter 2018 descent.
Read More
U.S. stocks continue to defy gravity, with their audacious 2019 year-to-date gains mirroring their equally extreme fourth quarter 2018 descent.
Read More
U.S. stocks delivered great performance in January and are now taking a breather. As such, I expect the S&P 500 index to trade between 2625 and 2825 for a while. The trading range might end up being a little higher or a little but...
Read More
The stock market recovery continues in a slightly better style than I had hoped for. I had expected big upswings followed by pullbacks, which is normal for a recovery.
Read More
Crista writes about four patterns she is looking at in the market.
Read More
Crista is adding a new stock to the Growth Portfolio, it's one of the world’s largest producers of nitrogen products, serving customers on six continents.
Read More
This will be a busy week for Wall Street as analysts speak with the companies within their stock purviews and write updated research reports. I expect to relay lots of changes in consensus earnings estimates in next week’s update.
Read More
Pharmas and Biotechs Dominated in 2015—Will They Do It Again in 2016?
In my January 9 Cabot Wealth Advisory, I wrote about the three top performers of 2015. Today, I take a look at the next nine top performers of 2015.
NeoPhotonics (NPTN) 3.37 to +223%...
Read More
In my January 9 Cabot Wealth Advisory, I wrote about the three top performers of 2015. Today, I take a look at the next nine top performers like NeoPhotonics (NPTN), 5 Intra-Cellular Therapies (ITCI) and others.
Read More
A person stops being a chump by finding a successful investing system that makes sense to them and then following it!
Read More
Today’s Daily Alert brings a new low-priced pharmaceutical stock idea from The CHEAP Investor.
“ArQule, Inc. (ARQL) engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib (ARQ 197) is an inhibitor of c-Met...
Read More